## **Amendments to the Claims**:

1.(Currently amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:

$$R^{a}$$
  $Y$   $C$   $N$   $R^{b}$   $R^{c}$   $R^{b}$ 

in which Ra is a group of formula (i)


$$(R^1)_{a}$$
  $p^1$ 

wherein P<sup>1</sup> is phenyl, naphthyl, or heteroaryl an aromatic ring containing 1 to 3 heteroatoms selected from the group consisting of O, N and S, or pyrazolyl;

 $R^1$  is halogen,  $C_{1\text{-}6}$ alkyl,  $C_{3\text{-}6}$ cycloalkyl,  $COC_{1\text{-}6}$ alkyl,  $C_{1\text{-}6}$ alkoxy, hydroxy, hydroxy $C_{1\text{-}6}$ alkyl, nitro,  $CF_3$ , cyano,  $SR^6$ ,  $SOR^6$ ,  $SO_2R^6$ ,  $SO_2NR^6R^7$ ,  $CO_2R^6$ ,  $CONR^6R^7$ ,  $OCONR^6R^7$ ,  $NR^6CO_2R^7$ ,  $NR^6CO_2R^7$ ,  $NR^6CONR^7R^8$ ,  $CR^6$ = $NOR^7$  where  $R^6$ ,  $R^7$  and  $R^8$  are independently hydrogen or  $C_{1\text{-}6}$ alkyl;

a is 0, 1, 2 or 3;

or Ra is a group of formula (ii)



wherein

P<sup>2</sup> is phenyl, naphthyl, or heteroaryl-or a 5 to 7 membered heterocyclic ring which is an aromatic ring containing 1, 2 or 3 heteroatoms selected from the group consisting of O, N, and S;

P<sup>3</sup> is phenyl, naphthyl or heteroaryl which is an aromatic ring containing 1, 2 or 3 heteroatoms selected from the group consisting of O, N, and S;

A is a bond or oxygen, carbonyl,  $CH_2$  or  $NR^4$  where  $R^4$  is hydrogen or  $C_{1-6}$ alkyl;

 $R^2$  is as defined above for  $R^1$  in formula (i) or  $R^2$  is heteroaryl optionally substituted by  $C_{1-6}$  alkyl, halogen or  $COC_{1-6}$  alkyl or is a 5 - 7 membered heterocyclic ring optionally substituted by oxo;

 $R^3$  is halogen,  $C_{1-6}$ alkyl,  $C_{3-6}$ cycloalkyl,  $C_{1-6}$ alkoxy,  $COC_{1-6}$ alkyl, hydroxy, nitro,  $CF_3$ , cyano,  $CO_2R^6$ ,  $CONR^6R^7$ ,  $NR^6R^7$  where  $R^6$  and  $R^7$  are as defined above; b and c are independently 0, 1, 2 or 3;

Y is a single bond,  $CH_2$ , O or  $NR^5$  where  $R^5$  is hydrogen or  $C_{1-6}$ alkyl;

W is - $(CR^9R^{10})_{t}$ - where t is 2, 3 or 4 and  $R^9$  and  $R^{10}$  are independently hydrogen or  $C_{1-6}$  alkyl or W is a group -CH=CH-;

 $R^b$  is hydrogen, halogen, hydroxy,  $C_{1\text{-}6}$  alkyl,  $CF_3$  ,  $COC_{1\text{-}6}$  alkyl, cyano or  $C_{1\text{-}6}$  alkoxy;  $R^c$  is hydrogen or  $C_{1\text{-}6}$  alkyl; and

Rd and Re are independently C<sub>1-4</sub>alkyl.

- 2.(Original) A compound according to claim 1 in which  $R^a$  is a group of formula (i) wherein  $P^1$  is phenyl.
- 3.(Original) A compound according to claim 2 in which  $R^1$  is halogen,  $C_{1-6}$ alkyl, nitro,  $CF_3$  or cyano.
- 4.(Previously Amended) A compound according to claim 1 in which Y is CH2.
- 5.(Original) A compound according to claim 1 in which  $R^a$  is a group of formula (ii) wherein A is a single bond,  $P^3$  is phenyl or naphthyl and  $P^2$  is phenyl, pyridyl, pyrazinyl, oxadiazolyl, oxazolyl or piperidinyl.
- 6.(Previously Amended) A compound according to claim 1 in which W is -CH<sub>2</sub>-CH<sub>2</sub>- or -CH=CH-.
- 7.(Previously Amended) A compound according to claim 1 in which R<sup>c</sup> is hydrogen or methyl.
- 8.(Previously Amended) A compound according to claim 1 in which  $R^d$  and  $R^e$  are both methyl.
- 9. (Currently Amended) A compound according to claim 1 which is cis-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-5-methoxy-1-[5-(6-methylpyridin-2-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

 $\label{cis-5-methoxy-1-[5-(2-methyloxazol-5-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl) indoline,} cis-5-methoxy-1-[5-(2-methyloxazol-5-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl) indoline,$ 

cis-1-(2,3-dichlorobenzoyl)-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-5-methoxy-1-[2'-methyl-4'-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-methoxy-1-[(3-nitrophenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-6-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthoyl]-1,2,3,4-tetrahydro-7-(3,4,5-trimethylpiperazin-1-yl)quinoline ,

cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2,3-dichlorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline,

cis-1-[(3-chloro-2-fluorophenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2,3-difluorophenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2,3-dichlorophenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2,3-dichlorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(3-chloro-2-fluorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2,3-difluorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthylacetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-chloro-1-[4-(6-methylpyridin-2-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[4-(2,6-dimethylpyridin-3-yl)-1-naphthoyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[4-(3,6-dimethylpyrazin-2-yl)-1-naphthoyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*eis*-5-methoxy-1-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline;

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-methyl-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(2-chloro-3-fluorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline, *cis*-1-[(2-bromo-3-fluorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-bromo-3-chlorophenyl)acetyl]-5-methoxy-6-(3,4,5- trimethylpiperazin-1-yl)indoline,

 ${\it cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxy in doline,}$ 

cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline,

cis-1-[(3-chloro-2-fluorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline,

cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-fluoro-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(3-fluoro-2-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(3-chloro-2-cyanophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(2-Acetyl-3-chlorophenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(3-bromo-2-methylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(3-cyano-2-methylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-5-bromo-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-Acetyl-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-5-methoxy-1-[(2-phenyl-3-(trifluoromethyl)pyrazol-4-ylcarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

 $\it cis$ -6-(3,5-dimethylpiperazin-1-yl)-1-[(4-(2,5-dimethylpyridin-4-yl)benzoyl]-5-methoxyindoline,

*cis*-6-(3,5-dimethylpiperazin-1-yl)-5-methoxy-1-[2'-methyl-4'-(2-oxopyrrolidin-1-yl)biphenyl-4-carbonyl]indoline,

cis-6-(3,5-dimethylpiperazin-1-yl)-5-methoxy-1-[4-(2-methyl-6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)benzoyl]-indoline,

*cis*-6-(3,5-dimethylpiperazin-1-yl)-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthoyl]indoline,

*cis*-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-5-cyano-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-[(3-aminocarbonyl-2-methylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-methoxy-1-[4-(1-methylpiperidin-4-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,)

 $\it cis-5-methoxy-1-[4-(piperidin-4-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl) indoline,$ 

cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indole,

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indole,

 ${\it cis-1-(2,3-dichlorophenylaminocarbonyl)-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)} indole,$ 

 $\label{cis-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthylacetyl]-6-(3,4,5-trimethylpiperazin-1-yl) indole,} \\$ 

cis-1-[(3-chloro-2-fluorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindole,

 $\it cis\hbox{-}1\hbox{-}[(2,3\hbox{-}dichlor ophenyl)acetyl]\hbox{-}6\hbox{-}(3,5\hbox{-}dimethyl piperazin\hbox{-}1\hbox{-}yl)\hbox{-}5\hbox{-}methoxy indole,}$ 

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-fluoro-6-(3,4,5-trimethylpiperazin-1-yl)indole,

*cis*-5-methoxy-1-[4-(6-methylpyridin-2-yl)-1-naphthylaminocarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-5-methoxy-1-[5-(6-methylpyridin-2-yl)-1-naphthylaminocarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-5-methoxy-1-[5-(2-methyloxazol-5-yl)-1-naphthylaminocarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-(2,3-dichlorophenylaminocarbonyl)-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-(3-chloro-2-fluorophenylaminocarbonyl)-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[3-fluoro-2-(trifluoromethyl)phenylaminocarbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[2-chloro-3-(trifluoromethyl)phenylaminocarbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

 ${\it cis-1-[2-chloro-3-methylphenyl)} a minocarbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl) indoline,$ 

*cis*-1-[2-chloro-3-(trifluoromethyl)phenyl)aminocarbonyl]-5-methyl-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-(2,3-dichlorophenylaminocarbonyl)-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-(2,3-dichlorophenylaminocarbonyl)-5-chloro-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-(2,3-dichlorophenylaminocarbonyl)-5-bromo-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-1-(2,3-dichlorophenylaminocarbonyl)-5-ethyl-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

cis-5-methoxy-1-[2-(trifluoromethyl)phenylaminocarbonyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[2-fluoro-3-(trifluoromethyl)phenylaminocarbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[2-chloro-3-(trifluoromethyl)phenylaminocarbonyl]-3,3-dimethyl-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

*cis*-1-[(2-chloro-3-trifluoromethyl)phenoxycarbonyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

or a pharmaceutically acceptable salt thereof.

- 10. (Currently Amended) A compound according to claim 1 which is cis-1-[(2-chloro-3-trifluoromethylphenyl)acetyl]-6-(3,4,5-trimethylpiperazin-1-yl)indole, cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-methoxy-6-(3,4,5-trimethylpiperazin-1-yl)indoline,
- *cis*-1-[(2,3-dichlorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindoline *cis*-6-(3,5-dimethylpiperazin-1-yl)-5-methoxy-1-[4-(2-methyl-6-(2-oxopyrrolidin-1-yl)pyridin-3-yl)benzoyl]-indoline,

cis-1-[(3-chloro-2-fluorophenyl)acetyl]-6-(3,5-dimethylpiperazin-1-yl)-5-methoxyindole,

cis-1-[(2-fluoro-3-trifluoromethylphenyl)acetyl]-5-fluoro-6-(3,4,5-trimethylpiperazin-1-yl)indole, or

*cis*-1-[2-chloro-3-(trifluoromethyl)phenyl)aminocarbonyl]-5-methyl-6-(3,4,5-trimethylpiperazin-1-yl)indoline,

or a pharmaceutically acceptable salt thereof.

- 11. (Currently Amended) A process for the preparation of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof which comprises:
- (a) where Y is NH, coupling a compound of formula (II):

$$R^{a}-N-(C=O)$$
  $R^{a}-NH-(C=O)$ 

(II)

in which R<sup>a</sup> is as defined in formula (I) with a compound of formula (III):

in which W, Rb, Rc, Rd and Re are as defined in formula (I); or

(b) where Y is NR<sup>5</sup>, reacting a compound of formula (IV)

in which R<sup>®</sup> and R<sup>5</sup> are as defined in formula (I) with a compound of formula (III) as defined above together with an appropriate urea forming agent; or

(eb) where Y is a single bond, CH2 or O, reacting a compound of formula (V)

$$R^a$$
 -Y- (C=O) - L (V)

in which R<sup>a</sup> is as defined in formula (I) and L is an appropriate leaving group, with a compound of formula (III) as defined above; and optionally thereafter for process (a), (b) or (c):

- removing any protecting groups,
- converting a compound of formula (I) into another compound of formula (I),
- forming a pharmaceutically acceptable salt.

12 - 13.(Cancelled)

14. (Previously Amended) A pharmaceutical composition which comprises a compound according to claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

15 - 16. (Cancelled).

17. (New) A method for treating depression in a mammal suffering same, which method comprises administering a therapeutically effective amount of a compound of formula I according to claim 1 or a pharmaceutially acceptable salt thererof alone or in admixture with a pharmaceutically acceptable carrier or excipient.

18. (New) A compound which is is *cis*-5-methoxy-1-[4-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-1-naphthoyl]-6-(3,4,5-trimethylpiperazin-1-yl)indoline or a pharmaceutically acceptable salt hereof.